Adicet Bio (ACET) vs Caribou Biosciences (CRBU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adicet Bio (ACET) has outperformed Caribou Biosciences (CRBU) over the past year, losing 61.4% versus a loss of 82.0%. Over five years, ACET leads with a -95.5% price change compared with -97.7% for CRBU. Adicet Bio is the larger company by market cap ($53.7 million vs $51.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | CRBU |
|---|---|---|
| Share price | $5.74 | $0.4812 |
| Market cap | $53.73M | $51.59M |
| 1-day change | -7.12% | -22.06% |
| YTD return | -31.83% | -69.74% |
| 1-year return | -61.38% | -82.04% |
| 5-year return | -95.54% | -97.69% |
| EPS (TTM) | $-10.42 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $3.54 |
| 52-week low | $5.55 | $0.45 |
| Distance from 52-week high | -67.09% | -86.39% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +506.79% | +1094.93% |
| Average volume | 172.38K | 2.14M |
| Shares outstanding | 9.36M | 107.21M |
| Employees | 102 | 97 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACET has outperformed CRBU by 20.7 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About Caribou Biosciences
CRBU stock →Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 97 employees
ACET vs CRBU FAQ
Which is bigger, Adicet Bio or Caribou Biosciences?
Adicet Bio (ACET) is larger, with a market capitalization of $53.73M compared with $51.59M for Caribou Biosciences (CRBU).
Which stock has performed better over the past year, ACET or CRBU?
ACET returned -61.38% over the past 12 months, compared with -82.04% for CRBU (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and Caribou Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Adicet Bio and Biotechnology: Biological Products (No Diagnostic Substances) for Caribou Biosciences.